



RECEIVED
SEP 17 2001
TECH CENTER 1600/2900

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)				Complete if Known				
				Application Number	09/815,597			
				Filing Date	March 23, 2001			
				First Named Inventor	Wolin			
				Group Art Unit	1632 1642			
Examiner Name	Not yet assigned A.M. Harris							
Sheet	1	of	1	Attorney Docket Number	PP01658.002 (035784/209107)			
U. S. PATENT DOCUMENTS								
Examiner Initials*	Cite No. ¹	U.S. Patent Document Number	Kind Code ² (if known)	Name of Patentee or Applicant Of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages of Relevant Figures Appear		
FOREIGN PATENT DOCUMENTS								
Examiner Initials	Cite No.	Foreign Patent Document Office ³	Number ⁴	Kind Code ⁵ (if known)	Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
SM	1	WO	00/09160	A1	IDEC Pharmaceuticals Corporation	02-24-2000	Whole Document	
NON PATENT LITERATURE DOCUMENTS								
Examiner Initials	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.						T
STAP	2	JANAKIRAMAN <i>et al.</i> (1998) "Rituximab: Correlation Between Effector Cells and Clinical Activity in NHL," <i>Blood</i> 10: 337a.						
STH	3	KEILHOLZ <i>et al.</i> (1999) "Rapid Regression of Chemotherapy Refractory Lymphocyte Predominant Hodgkin's Disease After Administration of Rituximab (Anti CD 20 Monoclonal Antibody) and Interleukin-2," <i>Leukemia and Lymphoma</i> 35: 641-642.						
SUN	4	LEGET <i>et al.</i> (1998) "Use of Rituximab, The New FDA-Approved Anti-body," <i>Current Opinion on Oncology</i> 10: 548-551.						
SM	5	MALONEY <i>et al.</i> (1998) "Newer Treatments for Non-Hodgkin's Lymphoma: Monoclonal Antibodies," <i>Oncology</i> 12: 63-76.						
STH	6	MALONEY <i>et al.</i> (1994) "Phase I Clinical Trial Using Escalating Single-Dose Infusion of Chimeric Anti-CD20 Monoclonal Antibody (IDEC-C2BB) in Patients with Recurrent B-Cell Lymphoma," <i>Blood</i> 84: 2457-2466.						
STH	7	YIRINEC <i>et al.</i> (1999) "Preliminary Report on Biological Effects of Rituxan (R) and Interleukin-2 (IL-2) in Patients with Low-Grade or Mantle Cell Non-Hodgkins Lymphoma (NHL)," <i>Blood</i> 94: 270b.						
Examiner Signature					Date Considered	9/30/03		

*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number.

² See attached Kinds of U.S. Patent Documents.

³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3).

⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document.

⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible.

⁶ Applicant is to place an "X" here if English language Translation is attached.

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT
(Use as many sheets as necessary)

Complete if Known

Application Number	09/815,597
Filing Date	March 23, 2001
First Named Inventor	Wolin
Group Art Unit	1632-1642
Examiner Name	Not yet assigned A.M. Harris
Attorney Docket Number	PP01658.002 (035784/209107)

Sheet 1 of 1

U. S. PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	U.S. Patent Document Number	Kind Code ² (if known)	Name of Patentee or Applicant Of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages of Relevant Figures Appear

FOREIGN PATENT DOCUMENTS

Examiner Initials	Cite No.	Foreign Patent Document Office ³	Number ⁴	Kind Code ⁵ (if known)	Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear

NON PATENT LITERATURE DOCUMENTS

Examiner Initials	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T
SM	45	HOOIJBERG, E., <i>et al.</i> , "Enhanced Antitumor Effects of CD20 over CD19 Monoclonal Antibodies in a Nude Mouse Xenograft Model," <i>Cancer Research</i> , February 15, 1995, pp. 840-846, Vol. 55(4), American Association for Cancer Research, Inc., USA.	
SM	46	HOOIJBERG, E., <i>et al.</i> , "Eradication of Large Human B Cell Tumors in Nude Mice with Unconjugated CD20 Monoclonal Antibodies and Interleukin 2," <i>Cancer Research</i> , June 15, 1995, pp. 2627-2634, Vol. 55(12), American Association for Cancer Research, Inc., USA.	

Examiner Signature	<i>[Signature]</i>	Date Considered	9/30/03
--------------------	--------------------	-----------------	---------

*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

RTA01/2107910v1

¹ Unique citation designation number.

² See attached Kinds of U.S. Patent Documents.

³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3).

⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document.

⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible.

⁶ Applicant is to place an "X" here if English language Translation is attached.

Substitute for form 1449A/PTO		Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT		Application Number	09/815,597
		Filing Date	March 23, 2001
		First Named Inventor	Wolin
		Group Art Unit	1632 1642
		Examiner Name	Not yet assigned Alana M. Hanks
Sheet O I P E of 3	Attorney Docket Number		PP01658.002 (035784/209107)

U. S. PATENT DOCUMENTS						
Examiner Initials	Cite No.	U.S. Patent Document		Name of Patentee or Applicant Of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages of Relevant Figures Appear
		Number	Kind Code (if known)			
SSH	8	4,816,567		Cabilly <i>et al.</i>	03-28-1989	
SSH	9	4,946,778		Ladner <i>et al.</i>	08-07-1990	
SSH	10	5,260,203		Ladner <i>et al.</i>	11-09-1993	
SSH	11	5,425,940		Zimmerman <i>et al.</i>	06-20-1995	
SSH	12	5,455,030		Ladner <i>et al.</i>	10-03-1995	
SSH	13	5,736,137		Anderson <i>et al.</i>	04-07-1998	
SSH	14	5,750,105		Newman <i>et al.</i>	05-12-1998	
SSH	15	5,756,096		Newman <i>et al.</i>	05-26-1998	
SSH	16	5,776,456		Anderson <i>et al.</i>	07-07-1998	
SSH	17	5,843,439		Anderson <i>et al.</i>	12-01-1998	
SSH	18	5,856,456		Whitlow <i>et al.</i>	01-05-1999	
SSH	19	5,939,598		Kucherlapati <i>et al.</i>	08-17-1999	
SSH	20	6,015,542		Kaminski <i>et al.</i>	01-18-2000	

FOREIGN PATENT DOCUMENTS								
Examiner Initials	Cite No.	Foreign Patent Document			Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T
		Office	Number	Kind Code (if known)				
SSH	21	WO	94/11026		IDEC Pharmaceuticals Corporation	05-26-1994		
SSH	22	WO	98/56418		Genentech, Inc.	12-17-1998		

Examiner Signature	<i>Shuff</i>	Date Considered	9/30/03
-----------------------	--------------	--------------------	---------

*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

RECEIVED
JAN 11 2002
TECH CENTER 1800/2900

O I P E
JAN 08 2002
PTO

Substitute for form 1449A/PTO		Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)		Application Number	09/815,597
		Filing Date	March 23, 2001
		First Named Inventor	Wolin
		Group Art Unit	1632 1642
		Examiner Name	Not yet assigned A.M. HARRIS
Sheet	3 of	Attorney Docket Number	PP01658.002 (035784/209107)

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials	Cite No.	Invention name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T
SJM	23	ALLISON, M.K., et al., "Phase II Trial of Outpatient Interleukin-2 in Malignant Lymphoma, Chronic Lymphocytic Leukemia, and Selected Solid Tumors," <i>Journal of Clinical Oncology</i> , January 1989, pp. 75-80, Vol. 7 (1).	
SJM	24	BERNSTEIN, Z.P., et al., "Prolonged Administration of Low-Dose Interleukin-2 in Human Immunodeficiency Virus - Associated Malignancy Results in Selective Expansion of Innate Immune Effectors without Significant Clinical Toxicity," <i>Blood</i> , November 1, 1995, pp. 3287-3294, Vol. 86 (9), The American Society of Hematology, USA.	
SJM	25	BERNSTEIN, Z.P., et al., "Interleukin-2 Lymphokine-Activated Killer Cell Therapy of Non-Hodgkin's Lymphoma and Hodgkin's Disease," <i>Journal of Immunotherapy</i> , 1991, pp.141-146, Vol. 10(2), 1991 Raven Press, Ltd., New York, USA.	
SJM	26	CARON, P.C., et al., "Interleukin-2 Enhancement of Cytotoxicity by Humanized Monoclonal Antibody M195 (Anti-CD33) in Myelogenous Leukemia," <i>Clinical Cancer Research</i> , January 1995, pp. 63-70, Vol. 1.	
SJM	27	CARSON, W.E., et al., "CD56 ^{bright} Natural Killer Cell Subsets: Characterization of Distinct Functional Responses to Interleukin-2 and the C-kit Ligand," <i>European Journal of Immunology</i> , 1997 pp. 354-360, Vol. 27, VCH Verlagsgesellschaft mbH, D-69451 Weinheim.	
SJM	28	COIFFIER, B., et al., "Rituximab (Anti-CD20 Monoclonal Antibody) for the Treatment of Patients with Relapsing or Refractory Aggressive Lymphoma: A Multicenter Phase II Study," <i>Blood</i> , September 15, 1998, pp. 1927-1932, Vol. 92(6), The American Society of Hematology, USA.	
SJM	29	DAVIS, T.A., et al., "Therapy of B-Cell Lymphoma with Anti-CD20 Antibodies Can Result in the Loss of CD20 Antigen Expression," <i>Clinical Cancer Research</i> , March 1999, pp. 611-615, Vol. 5.	
SJM	30	DUGGAN, D.B., et al., "A Phase II Study of Recombinant Interleukin-2 With or Without Recombinant Interferon- β in Non-Hodgkin's Lymphoma. A Study of the Cancer and Leukemia Group B," <i>Journal of Immunotherapy</i> , November 2, 1992, pp. 115-122, Vol. 12(2), 1992 Raven Press, Ltd., New York, USA.	
SJM	31	FROST, J.D., et al., "A Phase I/II Trial of Murine Monoclonal Anti-GD2 Antibody 14.G2a plus Interleukin-2 in Children with Refractory Neuroblastoma," <i>Cancer</i> , July 15, 1997, pp. 317-333, Vol. 80(2), American Cancer Society, USA.	
SJM	32	GISSELBRECHT, C., et al., "Interleukin-2 Treatment in Lymphoma: A Phase II Multicenter Study," <i>Blood</i> , April 15, 1994, pp. 2081-2085, Vol. 83(8), The American Society of Hematology, USA.	
SJM	33	HANK, J.A., et al., "Treatment of Neuroblastoma Patients with Antiganglioside GD ₂ Antibody plus Interleukin-2 Induces Antibody-Dependent Cellular Cytotoxicity Against Neuroblastoma Detected In Vitro," <i>Journal of Immunotherapy</i> , 1994, pp. 29-37, Vol. 15(1), 1994 Raven Press, Ltd., New York, USA.	
SJM	34	KHATRI, V.P., et al., "Ultra Low Dose Interleukin-2 Therapy Promotes a Type 1 Cytokine Profile In Vivo in Patients with AIDS and AIDS-Associated Malignancies," <i>Journal of Clinical Investigation</i> , March 1998, pp. 1373-1378, Vol 101(6), The American Society for Clinical Investigation, Inc., USA.	

Examiner Signature	<i>SJM</i>	Date Considered	9/30/03
-----------------------	------------	--------------------	---------

*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Substitute for form 1449A/PTO		Complete if known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)		Application Number	09/815,597
		Filing Date	March 23, 2001
		First Named Inventor	Wolin
		Group Art Unit	1632 1642
		Examiner Name	Not yet assigned A.M. Harf
Sheet 3 of 3	Attorney Docket Number	PP01658.002 (035784/209107)	

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials	No.	Incl. name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T
SSM	35	MALONEY, D.G., <i>et al.</i> , "IDEC-C2-B8 (Rituximab) Anti-CD20 Monoclonal Antibody Therapy in Patients with Relapsed Low-Grade Non-Hodgkin's Lymphoma," <i>Blood</i> , September 15, 1997, pp. 2188-2195, Vol. 90(6), The American Society of Hematology, USA.	
SSM	36	MALONEY, D.G., <i>et al.</i> , "IDEC-C2B8: Results of a Phase I Multiple-Dose Trial in Patients with Relapsed Non-Hodgkin's Lymphoma," <i>Journal of Clinical Oncology</i> , October 1997, pp. 3266-3274, Vol. 15(10), American Society of Clinical Oncology, USA.	
SSM	37	MCLAUGHLIN, P., <i>et al.</i> , "Rituximab Chimeric Anti-CD20 Monoclonal Antibody Therapy for Relapsed Indolent Lymphoma: Half of Patients Respond to a Four-Dose Treatment Program," <i>Journal of Clinical Oncology</i> , August 1998, pp. 2825-2833, Vol. 16(8), American Society of Clinical Oncology, USA.	
SSM	38	NAGLER, A., <i>et al.</i> , "Immunotherapy with Recombinant Human Interleukin-2 and Recombinant Interferon- α in Lymphoma Patients Postautologous Marrow or Stem Cell Transplantation," <i>Blood</i> , June 1, 1997, pp. 3951-3959, Vol. 89(11), The American Society of Hematology, USA.	
SSM	39	PARKINSON, D.R., <i>et al.</i> , "Biologic Therapies for Low-Grade Lymphomas," <i>Seminars in Oncology</i> , October 1993, pp. 111-117, Vol. 20(5), Suppl. 5.	
SSM	40	SHAN, D., <i>et al.</i> , "Apoptosis of Malignant Human B Cells by Ligation of CD20 with Monoclonal Antibodies," <i>Blood</i> , March 1, 1998, pp. 1644-1652, Vol. 91(5), The American Society of Hematology, USA.	
SSM	41	SZNOL, M., and D.R. Parkinson, "Interleukin-2 in Therapy of Hematologic Malignancies," <i>Blood</i> , April 15, 1994, pp. 2020-2022, Vol. 83(8), The American Society of Hematology, USA.	
SSM	42	VAN BESSEN, K., <i>et al.</i> , "Activity of Interleukin-2 in Non-Hodgkin's Lymphoma Following Transplantation of Interleukin-2-Activated Autologous Bone Marrow or Stem Cells," <i>The Cancer Journal from Scientific American</i> , 1997, pp. 130-132, Vol. 3(1), Suppl. 1, Scientific American.	
SSM	43	VLASVELD, L.T., <i>et al.</i> , "Treatment of Low-Grade Non-Hodgkin's Lymphoma with Continuous Infusion of Low-Dose Recombinant Interleukin-2 in Combination with the B-Cell-Specific Monoclonal Antibody CLB-CD19," <i>Cancer Immunology Immunotherapy</i> , 1995, pp. 37-47, Vol. 40.	
SSM	44	WEBER, J.S., <i>et al.</i> , "The Use of Interleukin-2 and Lymphokine-Activated Killer Cells for the Treatment of Patients with Non-Hodgkin's Lymphoma," <i>Journal of Clinical Oncology</i> , January 1992, pp. 33-40, Vol. 10(1).	

Examiner Signature	<i>Shuff</i>	Date Considered	9/30/03
--------------------	--------------	-----------------	---------

*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.